InteRNA Technologies

InteRNA Technologies last week announced that it is collaborating with the University of Bonn and Belgian biopharmaceutical firm UCB to identify and study microRNAs as therapeutic targets for neurodegenerative diseases.

NEW YORK (GenomeWeb News) – The European Union has provided €11.5 million ($15.4 million) to fund an international research consortium that will seek to investigate the roles microRNAs play in epilepsy and how they may be used to develop new diagnostics and treatments for the disease.

Dutch microRNA drug developer InteRNA Technologies this month announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering a number of novel microRNA sequences, including one that forms the basis of the company's l

Under the deal, InteRNA’s lentiviral-based miRNA over-expression library will be used in “multi-parametric, high-throughput functional screening assays” to identify the role of individual miRNAs in various cancer pathways. The company hopes to discover novel miRNAs as therapeutic targets.

The arrangement will take advantage of InteRNA's proprietary lentiviral-based miRNA over-expression library, according to the partners.

In doing so, SIROCCO is meeting its goal of making its discoveries and technologies freely accessible to the research community.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.